Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMS001 in Multiple Sclerosis
NCT04956744Phase 1Active, not recruiting
- Sponsor
- ImStem Biotechnology, Inc.
- Start
- Aug 2021
- Primary completion
- Dec 2027
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IMS001 in multiple sclerosis (MS) (3 arms), sponsored by ImStem Biotechnology, Inc. Primary endpoint: Safety and tolerability at Month 60. Started Aug 2021; status: active, not recruiting.
02
Drugs
IMS001
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04956744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956744.